Go online to PeerView.com/DRZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Atopic dermatitis (AD) carries a significant disease burden, and evidence shows there is often a mismatch in perception of disease severity between patients and their providers. Further, the treatment landscape is complex, with multiple approved therapies, including targeted biologic agents, which have revitalized treatment of the disease. Along with patient vignettes and a 3D-animated video clip, this activity features AD experts discussing the assessment of severity in AD, the underlying pathophysiology of AD, and the role of targeted therapy in reducing AD flares and achieving and maintaining control of the disease. Upon completion of this activity, participants should be better able to: Recognize the significant burden of moderate to severe atopic dermatitis (AD) on patients, including the impact of itch, depression, sleep disturbance, anxiety, and treatment dissatisfaction; Describe underlying mechanisms, including immunological and epidermal barrier dysfunction, that contribute to the development of AD and provide rationale for the use of targeted biologic therapy; and Select treatment for patients with moderate to severe AD, including biologic agents as appropriate, according to recent clinical evidence and current guidelines, with a goal of minimizing/preventing flares.
View all episodes
